Creso’s application to become Licensed Producer accepted by Health Canada

|

Published 08-OCT-2018 11:12 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Creso Pharma (ASX:CPH) this morning revealed that its Canadian subsidiary, Mernova Medicinal Inc., has smashed a major milestone — acceptance of its application for a cultivation license by Health Canada.

The successful application will transpire in a cultivation licence — one of the few to be issued to local companies in Nova Scotia.

Once the cultivation licence is in its hands, Mernova will plant its first cannabis crop in the new 24,000 square foot (2,200 square metre) purpose-built, indoor growing facility based in Windsor, Nova Scotia. The first crop is expected to be planted at the end of 2018.

Once two cannabis crops have been successfully grown, Mernova will then apply for a sale license — the final stage for producing commercial cannabis crops.

Mernova expects first revenues from the sale of cannabis in Q1, 2019.

On top of this, CPH has also inked a construction finance loan to fast-track development of the facility.

The terms have been finalised on a loan with a face value of A$2.7 million from L1 Capital Global Opportunities Master Fund and the Canadian Special Opportunity Fund. The loan has a drawdown price of 90% of the face value — CPH will receive A$2.42 million in funding to finalise construction of the growing facility.

With these two pivotal steps in place, CPH is now focused on fast-tracking production at its state-of-the-art growing facility to meet high and mounting demand for recreational and medicinal marijuana products.

The Mernova growing facility

Canada is set to legalise recreational marijuana use on October 17, making it the second country in the world, and the first industrialised nation, to fully legalise the drug.

This impending landmark, which has set many Canadian and US cannabis stocks ablaze, is also poised to create a flourishing industry extending beyond the already thriving medicinal cannabis market.

Canada’s recreational cannabis market sits somewhere between CA$4.9 billion to $8.7 billion, according to Deloitte Canada.

According to a recent report by CIBC analysts, once full legalisation kicks in, Canadian legal cannabis sales could reach CA$6.5 billion by 2020 — exceeding the CA$5.1 billion that Canadians spent on spirits in 2017 and coming close to the CA$7 billion spent on wine.

In 2017, US$2.25 billion was raised across 206 cannabis companies in Canada. In the first quarter of 2018 alone, over US$1.35 billion was raised across 96 Canadian cannabis companies, reflecting significant forecasted growth and demand.

Meanwhile, Canadian-listed cannabis companies that are similarly sized to CPH, with facilities of between 15,000 and 25,000 square feet, have an average market value of CA$64.95 million.

CPH plans to expand the Mernova facility by a further 200,000 square feet, putting the company in an excellent position to emerge as one of Canada’s leading producers.

CEO and co-founder, Dr. Miri Halperin Wernli, said that Creso is close to achieving one of its major strategic objectives — to supply consistent, high-quality medicinal cannabis products to its global markets.

“The purpose-built Mernova facility has been constructed to full GMP standards, making it superior to other cultivation facilities,” Halperin Wernlin said. “It is designed to produce three to four ton of dry cannabis annually.”

The licence has been accepted under the Access to Cannabis for Medical Purposes Regulations (ACMPR), and administered by Health Canada. The submission comprised comprehensive data, photos, videos and attestations by David Hyde & Associates Inc. — a renowned cannabis advisory firm which has consulted on 65 Licensed Producer (LP) sites and more than 300 LP applications, helping LPs navigate security and compliance in the highly regulated legalised cannabis space.

However, it is an early stage of this company’s development in these countries and if considering this stock for your portfolio, you should take all public information into account and seek professional financial advice.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X